. Author manuscript; available in PMC: 2023 May 18.

Published in final edited form as: Clin Cancer Res. 2023 May 15;29(10):1929–1937. doi: 10.1158/1078-0432.CCR-22-3233

Table 4.

Multivariable analysis of PSMA predicting PFS using the optimal cutoff for PSMA CTC positivity adjusting for prior therapy, CellSearch CTC and Halabi risk score.

	Cutoff (≥)	HR (95% confidence interval)
PSMA continuous	NA	1.05 (0.97–1.15)
PSMA continuous (log₂(x+1))	NA	1.30 (0.97–1.73)
PSMA negative (observed median cutoff)	1	1.44 (0.75–2.79)
PSMA positive (observed median cutoff)	1	1.90 (0.92–3.93)
PSMA negative (optimal cutoff)	2	1.51 (0.80–2.87)
PSMA positive (optimal cutoff)	2	2.28 (0.90–5.76)